Epilepsy: A Comprehensive Textbook
2nd Edition
© 2008 Lippincott Williams & Wilkins
←↑→
Z
Zafirlukast
1237
Zambia
2923–2927
Chikankata Epilepsy Care Team
2923
epilepsy care
barriers to
2923–2924
stigma and
2923–2924
health care
care plans
2926
data collection
2924–2925
financing of
2926
resource acquisition
2926–2927
stakeholders in
2925–2926
2925
overview
2923
prevalence of epilepsy
53
traditional views of epilepsy
43
Zellweger syndrome (ZS)
187
2608
Zheng Tai Instant Powder
1408
Zidovudine
718
795
1237
1354
Zinc, endogenous
294
Zinc ions
489
Ziprasidone
2234
Zitter rats
447
Zizyphi Fructus
1408
Zolpidem
246
Zone of cortical abnormality (ZCA)
1765–1766
Zonisamide (ZNS)
1695–1700
adverse effects
1260
1697
cognitive
2090
dose-related
1696–1697
idiosyncratic
1697
nephrolithiasis
1195
psychiatric
2165
teratogenicity
1218
1697–1698
chemistry
1695
clinical indications
1698–1699
contraindications
1699
discontinuation of
1699
dosage
1699
drug interactions
1243–1244
1265
1698
efficacy
1260
in epileptic myoclonus
2769
in infantile spasms
2333
in Lennox-Gastaut syndrome
2424
in migraine
2273
in myoclonus
597
in progressive myoclonus epilepsy
2532
for refractory epilepsy
1252
in simple motor seizures
525
elimination
2008
formulations
1699
history of
1432
indications
617
initiation schedule
1296
1296
licensing process
1511
mechanisms of action
1440–1442
1695–1696
2090
pharmacokinetics
1175
1238
pharmacology
1696
adsorption
1696
distribution
1696
elimination
1696
metabolism
1696
protein binding
1696
routes of administration
1696
in pregnancy
2071
prophylactic use of
1373–1374
sleep architecture and
1986
structure
1695
1696
therapeutic drug monitoring of
1180
Zung Self-Rating Anxiety Scale
2142
Zung Self-Rating Depression Scale
2142
←↑→